Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

PHASE3CompletedINTERVENTIONAL
Enrollment

774

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

February 5, 2017

Study Completion Date

March 10, 2017

Conditions
Bacterial PneumoniaCommunity-Acquired Infections
Interventions
DRUG

Omadacycline

Injection for IV; Oral tablets

DRUG

Moxifloxacin

IV solution; Oral tablets

Trial Locations (140)

14215

Site 506, Buffalo

25701

Site 516, Huntington

35215

Site 514, Birmingham

36608

Site 501, Mobile

45409

Site 509, Dayton

48202

Site 503, Detroit

55101

Site 520, Saint Paul

63110

Site 512, St Louis

70791

Site 511, Zachary

92653

Site 508, Laguna Hills

93003

Site 505, Ventura

06902

Site 513, Stamford

Unknown

Site 220, Liège

Site 276, Belo Horizonte

Site 277, Passo Fundo

Site 274, Porto Alegre

Site 279, São José do Rio Preto

Site 305, Kyustendil

Site 303, Pernik

Site 304, Plovdiv

Site 306, Sliven

Site 301, Sofia

Site 302, Sofia

Site 307, Sofia

Site 250, Požega

Site 205, Slavonski Brod

Site 212, Zadar

Site 201, Zagreb

Site 202, Zagreb

Site 203, Zagreb

Site 251, Zagreb

Site 405, Zagreb

Site 412, Kyjov

Site 410, Prague

Site 411, Prague

Site 414, Třebíč

Site 392, T'bilisi

Site 390, Tbilisi

Site 391, Tbilisi

Site 393, Tbilisi

Site 394, Tbilisi

Site 415, Heidelberg

Site 416, Jena

Site 417, Paderborn

Site 207, Athens

Site 420, Athens

Site 210, Athens

Site 421, Athens

Site 208, Thessaloniki

Site 310, Budapest

Site 311, Budapest

Site 312, Budapest

Site 314, Debrecen

Site 316, Miskolc

Site 313, Nyíregyháza

Site 315, Székesfehérvár

Site 213, Holon

Site 214, Nazareth

Site 217, Petah Tikva

Site 215, Ramat Gan

Site 216, Safed

Site 322, Daugavpils

Site 323, Liepāja

Site 320, Riga

Site 321, Riga

Site 228, Guadalajara

Site 472, Guadalajara

Site 227, Monterrey

Site 471, Monterrey

Site 230, Xalapa

Site 234, Cusco

Site 233, Lima

Site 236, Lima

Site 238, Lima

Site 239, Lima

Site 481, Lima

Site 237, Trujillo

Site 555, Caloocan City

552, Iloilo City

554, Manila

Site 551, Quezon City

Site 553, Quezon City

Site 332, Chrzanów

Site 333, Katowice

Site 330, Lodz

Site 331, Wroclaw

Site 334, Łęczna

Site 344, Brasov

Site 340, Bucharest

Site 342, Bucharest

Site 343, Bucharest

Site 345, Craiova

Site 341, Timișoara

352, Moscow

Site 350, Moscow

Site 351, Moscow

Site 353, Saint Petersburg

Site 354, Saint Petersburg

Site 355, Saint Petersburg

Site 356, Saint Petersburg

357, Sestroretsk

Site 358, Vsevolozhsk

Site 359, Zelenograd

Site 431, Bratislava

Site 430, Levice

Site 432, Martin

Site 433, Nitra

Site 241, Benoni

Site 436, Centurion

Site 242, Pretoria

Site 244, Thabazimbi

Site 245, Middelburg

Site 437, Somerset West

Site 293, Daegu

Site 291, Seoul

Site 292, Seoul

Site 294, Seoul

Site 225, Elche

Site 221, Barcelona

Site 440, Barcelona

Site 224, Alzira

Site 226, Alicante

Site 299, Kaohsiung City

Site 297, Tainan City

Site 295, Taipei

Site 296, Taipei

Site 298, Taipei

Site 247, Ankara

Site 248, Ankara

Site 249, Ankara

Site 246, Trabzon

Site 380, Dnipro

Site 373, Dnipropetrovsk

Site 374, Kharkiv

Site 375, Kharkiv

Site 370, Kyiv

Site 372, Kyiv

Site 378, Kyiv

Site 379, Kyiv

Site 376, Zaporizhia

Sponsors
All Listed Sponsors
lead

Paratek Pharmaceuticals Inc

INDUSTRY